tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Nevro Crop (NVRO), Cigna (CI) and United Therapeutics (UTHR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nevro Crop (NVROResearch Report), Cigna (CIResearch Report) and United Therapeutics (UTHRResearch Report).

Nevro Crop (NVRO)

J.P. Morgan analyst Robbie Marcus maintained a Hold rating on Nevro Crop yesterday and set a price target of $50.00. The company’s shares closed last Thursday at $45.46, close to its 52-week low of $39.41.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 8.8% and a 51.4% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Zimmer Biomet Holdings, and Baxter International.

The word on The Street in general, suggests a Hold analyst consensus rating for Nevro Crop with a $59.00 average price target, representing a 27.8% upside. In a report issued on July 20, Truist Financial also maintained a Hold rating on the stock with a $45.00 price target.

See the top stocks recommended by analysts >>

Cigna (CI)

In a report released today, Lisa Gill from J.P. Morgan maintained a Buy rating on Cigna, with a price target of $340.00. The company’s shares closed last Thursday at $280.10, close to its 52-week high of $284.46.

According to TipRanks.com, Gill is a 5-star analyst with an average return of 18.4% and a 66.5% success rate. Gill covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Privia Health Group, and Option Care Health.

Cigna has an analyst consensus of Moderate Buy, with a price target consensus of $300.06, a 6.9% upside from current levels. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $330.00 price target.

United Therapeutics (UTHR)

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on United Therapeutics, with a price target of $242.00. The company’s shares closed last Thursday at $221.35.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 9.6% and a 56.1% success rate. Fye covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Crinetics Pharmaceuticals, and Intra-Cellular Therapies.

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $252.25, implying an 11.7% upside from current levels. In a report issued on August 3, Credit Suisse also maintained a Buy rating on the stock with a $254.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More